SYK inhibitor
Fostamatinib
Brand names: Tavlesse
Adult dose
Dose: 100mg BD initially, increase to 150mg BD after 4 weeks if platelets <50
Route: PO
Frequency: BD
Clinical pearls
- Chronic ITP refractory to other therapies
- Specialist haematology
Contraindications
- Pregnancy
- Severe hepatic impairment
Side effects
- Hypertension
- Diarrhoea
- Hepatotoxicity
- Neutropenia
- Headache
- Nasopharyngitis
Interactions
- Strong CYP3A4 inhibitors/inducers
- Other hypertensive drugs
Monitoring
- BP
- FBC
- LFTs
Reference: BNF; NICE TA835; SmPC; https://bnf.nice.org.uk/drugs/fostamatinib/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO